- Home
- URGN vs PGC Comparison
URGN vs PGC Comparison
Compare URGN & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- PGC
- Stock Information
- Founded
- URGN 2004
- PGC 1921
- Country
- URGN United States
- PGC United States
- Employees
- URGN N/A
- PGC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- PGC Commercial Banks
- Sector
- URGN Health Care
- PGC Finance
- Exchange
- URGN Nasdaq
- PGC Nasdaq
- Market Cap
- URGN 465.9M
- PGC 540.4M
- IPO Year
- URGN 2017
- PGC N/A
- Fundamental
- Price
- URGN $11.06
- PGC $28.40
- Analyst Decision
- URGN Strong Buy
- PGC Buy
- Analyst Count
- URGN 6
- PGC 1
- Target Price
- URGN $40.75
- PGC $44.00
- AVG Volume (30 Days)
- URGN 418.3K
- PGC 98.5K
- Earning Date
- URGN 03-10-2025
- PGC 04-22-2025
- Dividend Yield
- URGN N/A
- PGC 0.71%
- EPS Growth
- URGN N/A
- PGC N/A
- EPS
- URGN N/A
- PGC 1.85
- Revenue
- URGN $90,398,000.00
- PGC $220,392,000.00
- Revenue This Year
- URGN $43.60
- PGC $26.92
- Revenue Next Year
- URGN $103.77
- PGC $15.51
- P/E Ratio
- URGN N/A
- PGC $15.31
- Revenue Growth
- URGN 9.29
- PGC 2.25
- 52 Week Low
- URGN $9.03
- PGC $20.30
- 52 Week High
- URGN $20.70
- PGC $37.88
- Technical
- Relative Strength Index (RSI)
- URGN 50.86
- PGC 35.74
- Support Level
- URGN $11.12
- PGC $28.47
- Resistance Level
- URGN $11.91
- PGC $29.94
- Average True Range (ATR)
- URGN 0.57
- PGC 1.09
- MACD
- URGN -0.02
- PGC 0.05
- Stochastic Oscillator
- URGN 26.40
- PGC 21.57
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Peapack Private Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and internet banking services. Peapack Private includes asset management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services.